The content on this site is intended for healthcare professionals only
ASCO 2018 conference round up
Repurposing selective PDE5 inhibitors as anti-cancer agents
First results of DREAM trial of frontline durvalumab for mesothelioma
Results from the phase I ICONIC trial
Chemotherapy plus durvalumab in triple negative breast cancer
Phase II results of olaparib and abiraterone for mCRPC
Global treatment pattern variations in HCC
Design and interim safety analysis of GeparX trial
International cancer control plans
Economic impact of NGS in non small cell lung cancer
Subcutaneous daratumumab shows benefit in patients with relapsed or refractory multiple myeloma
Avelumab in combinations for lung cancer and update from ALEX study
Updates in melanoma from ASCO 2018
Novel fusion proteins to target PD-L1 in HPV associated cancers
Daratumumab in combination with carfilzomib and dexamethasone for relapsed multiple myeloma
Phase I study results of M7824 for patients with HPV associated cancers
Phase III results of PROSPECT study for metastatic, castration-resistant prostate cancer
Pancreatic survival improved with trial chemotherapy regimen after surgery
Aspirin combined with acid-reducing medicine offers moderate benefits in patients with Barrett’s oesophagus
Pre-operative chemotherapy with radiation may help people with pancreatic cancer live longer
Heated abdominal chemotherapy not beneficial in patients with advanced colorectal cancer
Comment: Pancreatic cancer survival extended by over a year with chemotherapy regimen
Comment: Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals
Comment: Improved 2 year survival for pancreatic cancer with pre-operative chemoradiation
Comment: No benefit of heated abdominal chemotherapy in advanced colorectal cancer
Pancreatic cancer survival extended by over a year with chemotherapy regimen
Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals
Improved 2 year survival for pancreatic cancer with pre-operative chemoradiation
No benefit of heated abdominal chemotherapy in advanced colorectal cancer
Dabrafenib halts growth of low-grade paediatric glioma
Finding appropriate doses for HER2 positive breast cancers
Updates in targeted therapy for melanoma
Education, collaboration and communication in global cancer control
Health related quality of life findings from COMBI-AD
Developing a survivin vaccine for glioblastoma
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
New pathways in pancreatic cancer
OPTIMISMM trial for refractory multiple myeloma
Treatment updates in Merkel cell carcinoma
Results from the LILAC study of ABP 980 with trastuzumab for HER2 early breast cancer
New treatment markers for myeloma
Most breast cancer patients could avoid chemo with use of genetic testing
Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLC
Maintenance chemotherapy extends life for children with rare rhabdomyosarcoma
Sunitinib with or without surgery for metastatic renal cell carcinoma
Comment: Genetic testing of early breast tumours could allow patients to go without chemo
Comment: PD-1 immunotherapy better than chemo alone as first line lung cancer treatment
Comment: Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy
Comment: Kidney surgery may be unneeded in many intermediate-risk patients
Genetic testing of early breast tumours could allow patients to go without chemo
PD-1 immunotherapy better than chemo alone as first line lung cancer treatment
Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy
Kidney surgery may be unneeded in many intermediate-risk patients
Cancer treatment in the last 6 months of life: when inaction can outperform action
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer
Improving global breast cancer care
What will we expect from novel therapies for oesophageal and gastric malignancies?
Nelarabine in newly diagnosed paediatric T-cell malignancies
Immunotherapy trials and hyperprogressive disease
First-in-human phase 1 study of TAK-931 for solid tumours
Web-mediated follow-up via patient-reported outcomes vs. routine surveillance in lung cancer patients
The CAPTIVATE trial of ibrutinib and venetoclax as a first line treatment for CLL patients
Development of blood tests for early lung cancer
Linking Lynch Syndrome and microsatellite instability in tumours
Matching personalised therapies to patients in the IMPACT trial
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
Development of blood tests for early lung cancer
Matching mutations in tumours to precision medicine improves survival
Genomic study links several new cancers to Lynch Syndrome
Taselisib with fulvestrant slows growth of advanced breast cancer
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
